GH vs HELP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GH and HELP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GH and HELP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Guardant Health is a precision-oncology company that reads cancer signals from blood and tissue samples. Its business runs across three lines. Oncology, the largest, sells tests like Guardant360 (comprehensive genomic profiling that helps match patients to targeted therapies) and Guardant Reveal (a blood test for minimal residual disease, meaning traces of cancer left after treatment). Biopharma and Data sells testing, companion-diagnostic development, and real-world data to drugmakers. Screening is the newest and most-watched line: Shield is the first blood test to win full FDA approval as a primary screening option for colorectal cancer in average-risk adults 45 and older. In Q1 2026 the company reported ~$302 million in revenue, with oncology up 36% to ~$205 million on ~86,000 tests, biopharma and data at ~$53 million, and screening at ~$41.6 million on ~44,000 Shield tests (versus ~$5.7 million a year earlier).

Full GH guide

Helus Pharma Inc., which began trading on the Nasdaq under the ticker HELP in early 2026 (previously CYBN on NYSE American) and completed its legal name change from Cybin Inc. on October 1, 2026 after shareholders approved it on September 22, is a Toronto-based clinical-stage pharmaceutical company. The ticker did not change, and the shares also trade on Cboe Canada. Its lead program is HLP003 (also referenced as CYB003), a deuterated psilocybin analog with FDA Breakthrough Therapy Designation that is being studied as an adjunctive treatment for major depressive disorder in a registrational Phase 3 program called PARADIGM, which includes the APPROACH and EMBRACE studies. A second candidate, HLP004, a deuterated DMT compound, is in Phase 2 for generalized anxiety disorder. These are neuroactive serotonergic molecules designed to be administered in a supervised clinical setting.

Full HELP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GH drivers: Shield colorectal screening ramp; Core oncology growth and leverage.
• HELP drivers: Phase 3 depression readout; Anxiety program optionality.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Guardant is unprofitable and cash-consumptive, so it depends on the Shield launch converting into durable, reimbursed volume rather than one-off wins. For HELP, as a clinical-stage company, Helus has no revenue and posts ongoing net losses (about $171 million over the trailing twelve months as of October 2026), so it depends on trial success and repeated financing to survive.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GH if you believe its drivers more; HELP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GH and HELP guides.

GH. Figures are approximate and tied to the asOf date; verify live numbers before acting. GH trades near 18 times trailing sales, a multiple typical of a fast-growing, pre-profit diagnostics company, so the valuation is driven by expected future growth rather than current earnings. The stock more than doubled over the year to October 2026 but sits about 17% below its 52-week high of about $191, and the November 5 report (consensus revenue ~$351 million) plus the pace of Shield adoption and the 2027 breakeven timeline matter more than any single quarter.

HELP. Standard earnings multiples do not apply because Helus has no revenue and runs at a loss while funding Phase 3 trials. At roughly $784 million, the market value is now well above the ~$166 million cash balance, so investors are assigning a substantial premium to the pipeline ahead of the Q4 2026 Phase 3 data, a bigger bet than earlier in the year. Valuation will hinge on trial outcomes and any resulting financing rather than on current financials.

Headline figures (approximate, October 2026): GH shows revenue (ttm) ~$1.18 billion; Q2 2026 ~$335 million, up ~44% YoY, 2026 revenue outlook guided ~$1.30 to $1.32 billion earlier in 2026; consensus now ~$1.36 billion, gross margin (ttm) ~65%; operating margin ~-38%, net income (ttm) ~-$453 million loss; EPS ~-$3.50; HELP shows share price ~$10.73 (Oct 16, 2026), market cap ~$784M, revenue (ttm) $0 (pre-revenue), net loss (ttm) ~$171M.

GH and HELP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GH and HELP exposure against your real portfolio. It is not an investment adviser.